Shattuck Labs’ (STTK) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Shattuck Labs (NASDAQ:STTK) in a research report released on Thursday morning,Benzinga reports.

A number of other brokerages have also issued reports on STTK. Leerink Partners began coverage on Shattuck Labs in a research report on Monday, March 17th. They set an “outperform” rating and a $4.00 target price on the stock. Leerink Partnrs upgraded Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Shattuck Labs currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Stock Performance

Shares of STTK stock opened at $1.06 on Thursday. The firm has a market capitalization of $50.37 million, a PE ratio of -0.69 and a beta of 1.66. The stock has a fifty day moving average of $1.24 and a two-hundred day moving average of $1.48. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. Equities research analysts predict that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Institutional Trading of Shattuck Labs

Hedge funds and other institutional investors have recently modified their holdings of the company. Zacks Investment Management acquired a new position in Shattuck Labs in the 4th quarter worth about $25,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs in the 4th quarter valued at approximately $30,000. Atom Investors LP acquired a new position in Shattuck Labs in the third quarter worth approximately $35,000. Readystate Asset Management LP bought a new position in Shattuck Labs during the third quarter valued at approximately $39,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Shattuck Labs in the fourth quarter valued at approximately $45,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.